Our study evaluates the levels of astroglial activation (GFAP), microglial activation (CHI3L1 and sTREM2) and neuroaxonal damage (NfL) in CSF and serum of a multicentric cohort of PPMS-Patients. The gene discussed is GFAP; the disease is primary progressive multiple sclerosis.